CN105473144A - 用于加速斑块消退的组合物和治疗方法 - Google Patents
用于加速斑块消退的组合物和治疗方法 Download PDFInfo
- Publication number
- CN105473144A CN105473144A CN201480046366.0A CN201480046366A CN105473144A CN 105473144 A CN105473144 A CN 105473144A CN 201480046366 A CN201480046366 A CN 201480046366A CN 105473144 A CN105473144 A CN 105473144A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- rosuvastatin
- dimethoxyquinazoline
- oxethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361868386P | 2013-08-21 | 2013-08-21 | |
US61/868,386 | 2013-08-21 | ||
PCT/IB2014/002546 WO2015025226A2 (en) | 2013-08-21 | 2014-08-21 | Compositions and therapeutic methods for accelerated plaque regression |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105473144A true CN105473144A (zh) | 2016-04-06 |
Family
ID=52484226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480046366.0A Pending CN105473144A (zh) | 2013-08-21 | 2014-08-21 | 用于加速斑块消退的组合物和治疗方法 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20160206617A1 (pt) |
EP (1) | EP3035934A4 (pt) |
JP (1) | JP2016528275A (pt) |
KR (1) | KR20160043117A (pt) |
CN (1) | CN105473144A (pt) |
AU (1) | AU2014310369A1 (pt) |
BR (1) | BR112016003584A8 (pt) |
CA (1) | CA2921985A1 (pt) |
CL (1) | CL2016000379A1 (pt) |
EA (1) | EA201690284A1 (pt) |
HK (1) | HK1219434A1 (pt) |
IL (1) | IL244166A0 (pt) |
MX (1) | MX2016002302A (pt) |
WO (1) | WO2015025226A2 (pt) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115003306A (zh) * | 2020-01-08 | 2022-09-02 | 雷斯韦洛吉克斯公司 | 用bet溴结构域抑制剂和二肽基肽酶4抑制剂的组合治疗和/或预防主要不良心血管事件(mace)的方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101641339B (zh) | 2007-02-01 | 2013-07-17 | 雷斯韦洛吉克斯公司 | 用于预防和治疗心血管疾病的化合物 |
MX2021012876A (es) | 2009-03-18 | 2022-06-23 | Resverlogix Corp | Nuevos agentes anti-inflamatorios. |
ES2821018T3 (es) | 2009-04-22 | 2021-04-23 | Resverlogix Corp | Nuevos agentes antiinflamatorios |
PT2773354T (pt) | 2011-11-01 | 2019-07-17 | Resverlogix Corp | Formulações orais de libertação imediata para quinazolinonas substituídas |
US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
KR20160043118A (ko) * | 2013-08-21 | 2016-04-20 | 리스버로직스 코퍼레이션 | 가속화된 경화반 퇴행을 위한 조성물 및 치료방법 |
US10111885B2 (en) | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
MX2022005029A (es) * | 2019-11-05 | 2022-07-12 | Resverlogix Corp | Metodos de tratamiento y/o prevencion de acontecimientos cardiovasculares adversos graves (mace) con una combinacion de un inhibidor de bromodominio y extraterminal (bet) y un inhibidor de transporte de glucosa dependiente de sodio 2. |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101641339A (zh) * | 2007-02-01 | 2010-02-03 | 雷斯韦洛吉克斯公司 | 用于预防和治疗心血管疾病的化合物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ556545A (en) * | 2002-03-22 | 2009-03-31 | Novartis Ag | Combination comprising a beta-hydroxy-beta-methylglutaryl-co-enzyme-A reductase inhibitor and a glucagon-like peptide-1 agonist |
US20080085911A1 (en) * | 2006-10-10 | 2008-04-10 | Reliant Pharmaceuticals, Inc. | Statin and omega-3 fatty acids for reduction of apo-b levels |
EP2675445A1 (en) * | 2011-02-16 | 2013-12-25 | Pivotal Therapeutics, Inc. | Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases |
AU2014205553A1 (en) * | 2013-01-08 | 2015-07-09 | Volant Holdings Gmbh | Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems |
KR20160043118A (ko) * | 2013-08-21 | 2016-04-20 | 리스버로직스 코퍼레이션 | 가속화된 경화반 퇴행을 위한 조성물 및 치료방법 |
-
2014
- 2014-08-21 KR KR1020167007154A patent/KR20160043117A/ko not_active Application Discontinuation
- 2014-08-21 US US14/912,512 patent/US20160206617A1/en not_active Abandoned
- 2014-08-21 AU AU2014310369A patent/AU2014310369A1/en not_active Abandoned
- 2014-08-21 CN CN201480046366.0A patent/CN105473144A/zh active Pending
- 2014-08-21 WO PCT/IB2014/002546 patent/WO2015025226A2/en active Application Filing
- 2014-08-21 EP EP14837690.8A patent/EP3035934A4/en not_active Withdrawn
- 2014-08-21 BR BR112016003584A patent/BR112016003584A8/pt not_active IP Right Cessation
- 2014-08-21 CA CA2921985A patent/CA2921985A1/en not_active Abandoned
- 2014-08-21 MX MX2016002302A patent/MX2016002302A/es unknown
- 2014-08-21 JP JP2016535538A patent/JP2016528275A/ja not_active Withdrawn
- 2014-08-21 EA EA201690284A patent/EA201690284A1/ru unknown
-
2016
- 2016-02-17 IL IL244166A patent/IL244166A0/en unknown
- 2016-02-19 CL CL2016000379A patent/CL2016000379A1/es unknown
- 2016-06-29 HK HK16107584.9A patent/HK1219434A1/zh unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101641339A (zh) * | 2007-02-01 | 2010-02-03 | 雷斯韦洛吉克斯公司 | 用于预防和治疗心血管疾病的化合物 |
Non-Patent Citations (4)
Title |
---|
DANA BAILEY等: "RVX-208,A Small Molecule That Increases Apolipoprotein A-I and High-Density Lipoprotein Cholesterol In Vitro and In Vivo", 《JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY》 * |
STEPHEN J. NICHOLLS等: "ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies", 《CARDIOVASCULAR DRUGS AND THERAPY》 * |
STEPHEN J. NICHOLLS等: "Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease", 《JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY》 * |
无: "SUCCESSFUL ASSERT TRIAL RESULT IN RESVERLOGIX FILING NEW RVX-208 PATENT", 《HTTPS://WWW.RESVERLOGIX.COM/INVESTORS/NEWS?ARTICLE=453》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115003306A (zh) * | 2020-01-08 | 2022-09-02 | 雷斯韦洛吉克斯公司 | 用bet溴结构域抑制剂和二肽基肽酶4抑制剂的组合治疗和/或预防主要不良心血管事件(mace)的方法 |
Also Published As
Publication number | Publication date |
---|---|
EA201690284A1 (ru) | 2016-08-31 |
HK1219434A1 (zh) | 2017-04-07 |
EP3035934A4 (en) | 2017-04-26 |
BR112016003584A8 (pt) | 2018-01-30 |
KR20160043117A (ko) | 2016-04-20 |
WO2015025226A2 (en) | 2015-02-26 |
CA2921985A1 (en) | 2015-02-26 |
US20160206617A1 (en) | 2016-07-21 |
WO2015025226A9 (en) | 2015-12-03 |
MX2016002302A (es) | 2016-06-15 |
EP3035934A2 (en) | 2016-06-29 |
IL244166A0 (en) | 2016-04-21 |
CL2016000379A1 (es) | 2016-08-26 |
AU2014310369A1 (en) | 2016-03-10 |
JP2016528275A (ja) | 2016-09-15 |
AU2014310369A2 (en) | 2016-04-21 |
WO2015025226A3 (en) | 2015-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105473144A (zh) | 用于加速斑块消退的组合物和治疗方法 | |
CN105473145A (zh) | 用于加速斑块消退的组合物和治疗方法 | |
KR101699501B1 (ko) | 간기능부전 환자들에 대한 피르페니돈 치료법 | |
EP3626270B1 (en) | Treatment of cardiovascular diseases | |
WO2007106708A2 (en) | Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril | |
US20130296345A1 (en) | Methods for treating hyperuricemia and related diseases | |
EA028378B1 (ru) | Дейтерированные производные ивакафтора | |
TW201835071A (zh) | 4-嘧啶磺醯胺衍生物之結晶形式 | |
JP5978216B2 (ja) | テオフィリンとフェブキソスタットの併用療法のための方法 | |
JP6068765B2 (ja) | 薬学的複合製剤 | |
JP2023519890A (ja) | 免疫状態の処置のためのmk2経路阻害剤の経口組成物 | |
JP2023159438A (ja) | 神経原性起立性低血圧の処置に使用するための化合物 | |
EP2114154B1 (en) | Method of treating atherosclerosis, dyslipidemias and related conditions | |
JP3832229B2 (ja) | フェニルエテンスルホンアミド誘導体含有医薬 | |
JP2005505606A (ja) | Cox−2インヒビターおよびアスピリンを含んでなる組合せ剤 | |
CN102266333B (zh) | 一种含有左旋氨氯地平和阿托伐他汀钙的全新药用组合物及其制备方法 | |
US20070123498A1 (en) | Combination of organic compounds | |
Omae et al. | The use of H 1-receptor antagonists and left ventricular remodeling in patients on chronic hemodialysis | |
EP4360631A1 (en) | Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid | |
WO2020184703A1 (ja) | 大動脈瘤の治療用医薬組成物 | |
UA81290C2 (en) | Use of telmisartan and simvastatin, pharmaceutical composition and treatment method | |
TW201304775A (zh) | 使用依普羅沙坦與氨氯地平治療高血壓的組成物和方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160406 |
|
WD01 | Invention patent application deemed withdrawn after publication |